ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 829

Asymptomatic Deposit of Monosodium Urate Crystals Associates to a More Severe Coronary Calcification in Hyperuricemic Patients with Acute Coronary Syndrome

Mariano Andrés1, María Amparo Quintanilla2, Francisca Sivera1, Paloma Vela3,4 and Juan Miguel Ruiz-Nodar5, 1Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain, 2Sección de Cardiología, Hospital General Universitario de Elda, Alicante, Spain, 3Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, 4Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, 5Servicio de Cardiología, Hospital General Universitario de Alicante, Alicante, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis, Cardiovascular disease, coronary artery disease, crystal-induced arthritis and hyperuricemia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies I: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Increased cardiovascular (CV) risk in gout relates to crystal-driven inflammation. Monosodium urate (MSU) crystals are found in ~25% of patients with asymptomatic hyperuricemia (AH) by ultrasound (US) [1,2]. Whether AH patients with crystal deposits depict an increased CV risk has not been assessed so far. We aimed to assess the association between the deposit of MSU crystals in AH and the severity and extension of the coronary atherosclerotic disease (CAD).

Methods: Cross-sectional study, approved by the local ethics committee. Consecutive patients with AH (serum uric acid [SUA] >7.0 mg/dL) admitted due to an acute coronary event were selected. Those with current urate lowering treatment (ULT) were excluded. US of both knees and 1stMTP joints was performed to detect signs of MSU crystals deposition: doble contour sign, snow storm sign, tophus or joint effusion. When present, US-guided arthrocentesis was performed to confirm MSU crystals by polarised light microscopy. US and microscopy findings were later reviewed by a blinded rheumatologist. CAD was assessed through the severity of coronary artery calcification (absent, mild, moderate or severe) and the total of significant coronary lesions (>50% of the diameter) at coronariography by a blinded cardiologist. Traditional CV risk factors were also collected. Association between coronariographic features and crystal identification was analysed by logistic regression for binary variables and lineal regression for continous variables.

Results: Fifty-one patients were enrolled, median (p25-75) age 73 years (59-81), 76.5% males. Median SUA at admission was 7.6 mg/dL (7.08-8.6). Moderate-to-severe calcification was present in 21 (41.2%) patients, and the median number of significant coronary lessions was 3.0 (2-5). US found lesions in 49 (96.0%) patients: joint effusion in 94.1%, tophi in 9.8%, doble contour sign in 9.8% and snow storm sign in 3.9%. Arthrocentesis was performed in 48 patients. MSU crystals were identified in 11 patients (21.6% of total). No significant differences between groups were found in traditional CV risk factors or SUA levels. The presence of moderate to severe coronary calcification significantly differed between groups and strongly associate to the detection of MSU crystals [Table]. The number of significant lesions did not associate to MSU crystals identification, though a trend tomards more lesions in MSU+ patients was noted.

Conclusion: Our study found a more severe coronary calcification in those AH patients with deposits of MSU crystals. These patients might benefit from ULT aiming to reduce their CV risk, but this should be addressed in future studies.

References: [1] Arthritis Res Ther; 13:R4. [2] Ann Rheum Dis; 71:157.

Table.

 

MSU+ patients

(n= 11)

MSU- patients

(n=40)

p-value

Association analysis

Moderate-severe coronary calcification

(n,%)

8 (72.7%)

13 (32.5%)

0.016

OR 9.406+

(95%CI 1.459, 60.637)

Significant coronary lesions

(median, p25-75)

4.0

(3.0-5.0)

3.0

(1.3-4.0)

0.137

β 0.693

(95%CI -0.596, 1.982)

R2 0.003

MSU: monosodium urate; OR: odds ratio; CI: confidence interval. + Model adjusted for age, gender, hypertension, diabetes, dyslipemia, smoking, glomerular filtration rate and serum uric acid at admission.


Disclosure:

M. Andrés,
None;

M. A. Quintanilla,
None;

F. Sivera,
None;

P. Vela,
None;

J. M. Ruiz-Nodar,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/asymptomatic-deposit-of-monosodium-urate-crystals-associates-to-a-more-severe-coronary-calcification-in-hyperuricemic-patients-with-acute-coronary-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology